| Abstract | BACKGROUND: Serum albumin (S-Alb), C-reactive protein (CRP), and interleukin 6 (IL-6) predict malnutrition, atherosclerotic cardiovascular disease (CVD), and mortality in patients with end-stage renal disease (ESRD). Fetuin A, an inhibitor of vascular calcification, also is associated strongly with clinical outcome in patients with ESRD. In this study, multivariate analyses were performed to assess these 4 biomarkers as predictors of malnutrition, CVD, and mortality in patients with ESRD. METHODS: One hundred seventy-six patients with ESRD (54 +/- 12 years) underwent measurements of S-Alb, high-sensitivity CRP (hs-CRP), plasma IL-6, and fetuin A close to the start of dialysis therapy and were followed up for a median of 26 months (range, 1 to 66 months). Nutritional status was evaluated by means of subjective global assessment. CVD was defined based on medical history. Associations between biomarker levels and malnutrition, CVD, and mortality were evaluated by means of receiver operating characteristic curve, logistic regression analysis, and Cox proportional hazards model. RESULTS: All 4 biomarkers predicted malnutrition, CVD, and mortality. Multivariate analysis, according to receiver operating characteristic analysis, showed that malnutrition was predicted best by hs-CRP and IL-6 levels; CVD, by IL-6 level; and mortality, by albumin and IL-6 levels. When using the cutoff levels derived from receiver operating characteristics, logistic regression analysis showed that only hs-CRP level (odds ratio [OR], 3.6) was associated with malnutrition, and only IL-6 level (OR, 3.7) was associated with CVD. Levels of S-Alb, IL-6, and fetuin A, but not hs-CRP, were associated with increased relative risk for mortality as assessed by Cox in a model adjusting for age, sex, and diabetes mellitus. CONCLUSION: Multivariate analyses show that in patients with ESRD, malnutrition is predicted best by hs-CRP and IL-6 levels; CVD, by IL-6 level; and mortality, by S-Alb, IL-6, and fetuin A levels, but not by hs-CRP level. This comparative analysis indicates that of these biomarkers, IL-6 level may be the most reliable predictor of CVD and mortality in patients with ESRD. |
| Authors | Hirokazu Honda, Abdul Rashid Qureshi, Olof Heimbürger, Peter Barany, Kai Wang, Roberto Pecoits-Filho, Peter Stenvinkel, Bengt Lindholm
(Affiliation: Division of Renal Medicine, Department of Clinical Science, Interventions and Technology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.)
|
| Journal | American journal of kidney diseases : the official journal of the National Kidney Foundation
(Am J Kidney Dis)
Vol. 47
Issue 1
Pg. 139-48
(Jan 2006)
ISSN: 1523-6838 [Electronic] United States |
| PMID | 16377395
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antihypertensive Agents
- Antilipemic Agents
- Biological Markers
- Interleukin-6
- Serum Albumin
- alpha-Fetoproteins
- C-Reactive Protein
|
| Topics |
- Adult
- Aged
- Antihypertensive Agents
(therapeutic use)
- Antilipemic Agents
(therapeutic use)
- Biological Markers
- C-Reactive Protein
(analysis)
- Cardiovascular Diseases
(blood, diagnosis, epidemiology)
- Comorbidity
- Cross-Sectional Studies
- Diabetes Mellitus
(epidemiology)
- Female
- Follow-Up Studies
- Humans
- Hyperlipidemias
(drug therapy, epidemiology)
- Hypertension
(drug therapy, epidemiology)
- Interleukin-6
(blood)
- Kidney Failure, Chronic
(blood, epidemiology, mortality)
- Kidney Function Tests
- Logistic Models
- Male
- Malnutrition
(blood, diagnosis, epidemiology)
- Middle Aged
- Predictive Value of Tests
- Proportional Hazards Models
- ROC Curve
- Serum Albumin
(analysis)
- Survival Analysis
- alpha-Fetoproteins
(analysis)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research network!
Research Interface PRO additionally includes
drill-down to evidence,
articles by author,
export to Excel,
FDA Link and
mobile subscription:
1 year subscription, $45.00 USD
    
|